Screener
Crinetics Pharmaceuticals CRNX Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001658247-26-000040
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Interest income | 12,664 | 14,834 |
| Other expense, net | (131) | (203) |
| Total other income, net | 12,533 | 14,631 |
| Net loss | (127,845) | (96,774) |
| Net loss per share: | ||
| Net loss per share — basic and diluted | $(1.23) | $(1.04) |
| Weighted average shares — basic and diluted | 104,099 | 93,102 |
| Other comprehensive income (loss): |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Crinetics Pharmaceuticals's net income?
- Crinetics Pharmaceuticals (CRNX) reported net income of -$127.85M in Q1 2026.
- How has Crinetics Pharmaceuticals's net income changed year-over-year?
- Crinetics Pharmaceuticals's net income decreased by 32.1% year-over-year, from -$96.77M to -$127.85M.
- What is the long-term trend for Crinetics Pharmaceuticals's net income?
- Over 4 years (2021 to 2025), Crinetics Pharmaceuticals's net income has grown at a 44.2% compound annual growth rate (CAGR), from -$107.64M to -$465.32M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Crinetics Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude